Aim: Considering the poor long-term success of current dietary and pharmacological interventions, we aimed to evaluate the potential effect of sodium tungstate in the treatment of grade I and II obesity (ClinicalTrials.gov identifier: NCT00555074).

 

Methods: Prospective, randomized, placebo-controlled, double-blind, proof-of-concept study was carried out. Following a 2-week lead-in period, 30 obese (body mass index, BMI 30.0–39.9 kg/m2), non-diabetic subjects were randomized to receive either sodium tungstate (100 mg bid) or placebo for 6 weeks. The primary study endpoint was the absolute change in body weight relative to the time of randomization.

 

Results: Treatment with sodium tungstate [−0.135 ± 0.268 kg (95% CI −0.686 to +0.416 kg)] was not associated with a significant weight loss compared to placebo [−0.063 ± 0.277 kg (95% CI −0.632 to +0.507 kg)] (p = 0.854). Likewise, treatment with sodium tungstate was not associated with significant changes in fat mass (DEXA), resting energy expenditure (indirect calorimetry) or caloric consumption (3-day food records).

 

Conclusion: Our data do not support sodium tungstate as a pharmacological agent in the treatment of human obesity.

Tungsten Powder Manufacturer & Supplier: Chinatungsten Online - www.tungsten-powder.com
Tel.: 86 592 5129696; Fax: 86 592 5129797
Email: sales@chinatungsten.com
Tungsten & Molybdenum Information Bank: http://i.chinatungsten.com
Tungsten News & Tungsten Prices, 3G Version: http://3g.chinatungsten.com
Molybdenum News & Molybdenum Price: http://news.molybdenum.com.cn